Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa plus standard chemotherapy in relapsed ovarian cancer
2013-001323-38Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Jul 2013
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in epithelial ovarian cancer (EOC) comparing DCVAC/OvCa + standard of care chemotherapy with Standard of care chemotherapy (2 arms). Primary endpoint: Progression-free survival (PFS). Started Jul 2013; status: completed.
02
Drugs
DCvac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2013-001323-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001323-38.